PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 1, 1996American Journal of HypertensionOpen Access

Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does bosentan reduce blood pressure and vascular/renal hypertrophy in DOCA-salt treated spontaneously hypertensive rats?

Population

Deoxycorticosterone acetate and salt-treated spontaneously hypertensive rats model of malignant hypertension

Comparison

Bosentan 100 mg/kg/day mixed with food vs Untreated DOCA-salt SHR

Design

Preclinical

Authors

JLJing Li

Discussion

Loading...

Member takes

Overview

Bosentan reduces blood pressure and small artery vascular hypertrophy in a rat model of malignant hypertension, though renal protection was not unambiguously demonstrated.

Structured PICO

Does bosentan reduce blood pressure and vascular/renal hypertrophy in DOCA-salt treated spontaneously hypertensive rats?

P
Population
Deoxycorticosterone acetate (DOCA) and salt-treated spontaneously hypertensive rats (SHR) model of malignant hypertension
I
Intervention
Bosentan 100 mg/kg/day mixed with food
C
Comparator
Untreated DOCA-salt SHR
O
Outcome
Blood pressure, vascular hypertrophy, and pathologic renal changessurrogate

Bosentan reduces blood pressure and small artery vascular hypertrophy in a rat model of malignant hypertension, though renal protection was not unambiguously demonstrated.

Cite This Study

Jing Li (1996) studied this question.

synapsesocial.com/papers/6a7247c535aa2c282ce32cc9https://doi.org/10.1016/0895-7061(96)00100-8
View Full Paper
Ask AI
Bookmark
Share